17th North American Regional ISSX Meeting (October 16

P112

An in vitro test system to evaluate drug-drug interactions with biologics
Maciej Czerwinski, XenoTech, LLC; Christina Renneke, Viracor IBT Laboratories; Joanne Parker, Viracor IBT Laboratories; Chad Pope, XenoTech, LLC; Kevin Lyon, XenoTech, LLC; Catherine Wiegand, XenoTech, LLC; Jason Neat, XenoTech, LLC; Faraz Kazmi, XenoTech, LLC; David Buckley, XenoTech, LLC; Andrew Parkinson, XenoTech, LLC

P113

Can Lysosomal Trapping Cause Drug-Drug Interaction?
Mingxiang Liao, Millennium Pharmaceuticals, Inc.; Mi-Sook Kim, Millennium Pharmaceuticals, Inc.; Qing Zhu, Millennium Pharmaceuticals, Inc.; Lili Yao, Millennium Pharmaceuticals, Inc.; Bingli Ma, Millennium Pharmaceuticals, Inc.; Bei-Ching Chuang, Millennium Pharmaceuticals, Inc.; Jing-Tao Wu, Millennium Pharmaceuticals, Inc.; Suresh K. Balani, Millennium Pharmaceuticals, Inc.; Frank W. Lee, Millennium Pharmaceuticals, Inc.; Cindy Xia, Millennium Pharmaceuticals, Inc.

P114

Development of a Rapid Cell-based Assay using Flow Cytometry for Assessing Drug Interactions with Human Sodium-dependent Taurocholate Cotransporting Polypeptide (NTCP)
Steve Wright, Carson-Newman College; J. Li, Absorption Systems LP; Y. Wang, Absorption Systems LP; A. Owen, Absorption Systems LP; I.J. Hidalgo, Absorption Systems LP

P115

Impact of marker detection on in vitro in vivo extrapolation of CYPs induction. Enzymatic activity versus mRNA
Patrice Dehanne, Aureus Sciences; Estelle Rapine, Aureus Sciences; Olivier Barberan, Aureus Sciences

P116

Inactivation of CYP2C8 by gemfibrozil 1-O-B-glucuronide accumulation in human hepatocytes: Implications for clinical DDI predictions
Andrea Whitcher-Johnstone, Boehringer Ingelheim Pharmaceuticals Inc.; Tom S. Chan, Boehringer Ingelheim Pharmaceuticals Inc.

P118

Modulation of Hepatic UGT Function by IL-6 and TNFá and its Relationship with the PXR, CAR, and AhR
Jin Zhou, Alliance Pharma, Inc.; Shawn Li, Alliance Pharma, Inc.; Feng Li, Alliance Pharma, Inc.

P119

N-Glucuronidation of midazolam increases in the presence of a CYP3A inhibitor in both human hepatocytes and human volunteers
Kosea S. Frederick, Boehringer-Ingelheim; Jennie Schmenk, Boehringer-Ingelheim Pharmaceuticals; Mary F. Paine, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill; Cathrine L. Denton, The University of North Carolina at Chapel Hill; Michael Fisher, Boehringer-Ingelheim Pharmaceuticals

P120

Predicting Transporters Mediated Drug Interactions based on the Mechanistic Static Approach. Application to Statins
Olivier Barberan, Aureus Sciences; Estelle Rapine, Aureus Sciences; Amélie Moreau, Technologie Servier; Georges Daviolante, Technologie Servier

P121

Prediction of Clearance Changes of Drugs that are Substrates of Major Cytochrome P450 Enzymes Caused by Drug-Drug Interaction or Single Nucleotide Polymorphism
Akihiro Hisaka, The University of Tokyo Hospital; Yoshiyuki Ohno, The University of Tokyo Hospital; Ryo Yamaguchi, The University of Tokyo Hospital; Masaki Ueno, The University of Tokyo Hospital; Kousei Ito, The University of Tokyo Hospital; Hiroshi Suzuki, The University of Tokyo Hospital

P122

THE USEFULNESS OF OATP INHIBITOR AS A TOOL OF IN VITRO DRUG-DRUG INTERACTION STUDY USING HUMAN HEPATOCYTE
Shinsuke Aoyama, Sekisui Medical Co., Ltd.; Miki Fujishima, Sekisui Medical Co., Ltd.; Takami Sarashina, Sekisui Medical Co., Ltd.; Teruhiko Yanagisawa, Sekisui Medical Co., Ltd.; Kiyoe Morita, Sekisui Medical Co., Ltd.; Yasuhisa Adachi, Sekisui Medical Co., Ltd.; Shin-ichi Ninomiya, Sekisui Medical Co., Ltd.

P123

Target delivery in traditional Chinese medicine
Ruizhi Zhao, Guangzhou university of triditional Chinese medicine

P124

The Rate of Hydrolysis of AZD3043 is Dependent on the Butyrylcholinesterase Genotype and Independent of other Butyrylcholinesterase Substrates
Jenny Aasa, CNSP AstraZeneca R&D Södertälje; Antti Kautiainen, CNSP AstraZeneca R&D Södertälje; Stéphane Barassin, CNSP AstraZeneca R&D Södertälje; Anne-Marie Sims, AstraZeneca R&D, Alderly Park, UK; Clive Brealey, R&I AstraZeneca R&D, Mölndal, Sweden

P125

Time-Dependent Inactivation And Estimation Of CYP3A4 Clinical Pharmacokinetic Drug-Drug Interactions Using Plated Hepatocytes
Daniel R. Albaugh, Boehringer-Ingelheim Pharmaceuticals, Inc.; Cody L. Fullenwider, Boehringer-Ingelheim Pharmaceuticals, Inc.; David P. Joseph, Boehringer-Ingelheim Pharmaceuticals, Inc.; J. Matthew Hutzler, Boehringer-Ingelheim Pharmaceuticals, Inc.; Michael B. Fisher, Boehringer-Ingelheim Pharmaceuticals, Inc.

P126

Time-dependent inactivation of cytochrome P450 3A by imatinib: implications for its clinical pharmacokinetics and drug interactions
Yang Xu, Amgen Inc.; Yuping Chen, Amgen Inc.; Yihong Zhou, Amgen Inc.; Shuguang Ma, Amgen Inc.; Mike Hayashi, Amgen Inc.; Yvonne Pan, Amgen Inc.; Gary L. Skiles, Amgen Inc.; Magang Shou, Amgen Inc.

P127

Using the Cynomolgus Monkey as a Model to Assess Cytochrome P450 3A (CYP3A) Induction Potential Prior to First-in Man: A Case Study
Aberra Fura, Bristol-Myers Squibb; Sean Kim, Bristol-Myers Squibb; Mary Obermeier, Bristol-Myers Squibb; Zheng Yang, Bristol-Myers Squibb; David Rodrigues, Bristol-Myers Squibb

P128

What kind of assumptions should we use to improve the predictability of drug-drug interactions involving organic anion transporting polypeptide (OATP) substrates?
Kazuya Maeda, The university of Tokyo; Kenta Yoshida, The university of Tokyo; Yuichi Sugiyama, The university of Tokyo